Floatz logo

Avandia

Lipodystrophy

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lipodystrophy cohort.

Asset / SponsorPhaseRating
Efavirenz
Juan A. Arnaiz
Phase 4A
Lamivudine
Thomas Benfield
Phase 4BBB
ZIDOVUDINE
Kirby Institute
Phase 4BBB
Abacavir
Kirby Institute
Phase 4BBB
PRAVASTATIN
Kirby Institute
Phase 4BBB

View all 50 →

Same molecule, other indications

Avandia is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative ·
53 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
HIV infectious diseaseDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →